Introduction {#s1}
============

Oct4 is a key transcription factor (TF) in the pluripotency regulatory network ([@bib11]; [@bib18]; [@bib33]; [@bib46]). Previous studies have suggested that Oct4 drives cell lineage commitment in a dose-dependent manner ([@bib43]; [@bib68]), switching gene regulatory regions ([@bib3]) by diffusive behaviors ([@bib24]; [@bib51]) and mediating changes in chromatin structure ([@bib1]; [@bib14]; [@bib22]). The mechanism by which Oct4 is able to specify naive cells in a pluripotent state into one of the three germ layers is not completely understood. The function of TFs can be modulated by their interactions with other TFs ([@bib50]). In vitro assays of Oct4 protein interactions have been performed ([@bib32]; [@bib71]; [@bib73]); however, they do not reflect the complexity of a live embryo and do not provide information about the spatiotemporal complex formation that occurs during embryonic development. Therefore, to determine the mechanism by which Oct4 regulates cell fate decisions and patterning, it is important to investigate Oct4 complex formation with other TFs in the context of a developing embryo.

Mammalian Pou5f1/Oct4 can functionally replace its paralogue Pou5f3 ([@bib21]) in zebrafish embryos, with evidence showing that overexpressed Oct4 can rescue the phenotype of maternal-zygotic (MZ) *spg* embryos that lack Pou5f3 function ([@bib44]). Maternal Pou5f3 regulates dorsoventral (DV) patterning ([@bib9]; [@bib54]) and endoderm formation ([@bib34]; [@bib55]), whereas the establishment of the mid--hindbrain boundary requires zygotic expression of Pou5f3 ([@bib8]; [@bib53]). Pou5f3 induces mesendoderm ventralization through activation of the BMP pathway and the expression of the Vent (Vent, Ved and Vox) family of TFs ([@bib54]). In addition, although Pou5f3 is required in mesendoderm progenitors for *sox17* activation to specify endoderm formation ([@bib34]; [@bib55]), it is not required for upstream regulators of endoderm, which are properly induced in MZ*spg* ([@bib34]; [@bib55]). In contrast, Nanog is critical for endoderm induction through the Mxtx-Nodal pathway where it induces *sox32* in mesendodermal cells and other early, endoderm regulators, such as *gata5, mixer, nrd1* and *nrd2* ([@bib79]). Uniquely, Sox32, in the presence of Pou5f3, activates *sox17* expression in endodermal cells ([@bib4]; [@bib25]; [@bib34]; [@bib55]).

Loss- and gain-of-function genetics experiments, as well as investigations at the mRNA level, have sought to identify various roles for Pou5f3 ([@bib8]; [@bib12]; [@bib34]; [@bib44]; [@bib54]), Nanog ([@bib59]; [@bib79]) and Sox32 ([@bib25]; [@bib55]) during zebrafish development. Here, we exploit fluorescence lifetime imaging microscopy (FLIM) and fluorescence correlation spectroscopy (FCS) to study, at the protein level, the TF complexes and dynamics that underlie cell fate commitment in vivo. We present a quantitative model to describe how Pou5f3--Nanog complexes, modulated by Sox32, can specify mesendoderm cell lineage differentiation in a spatiotemporal manner along the DV axis.

Results {#s2}
=======

Pou5f3-bound active fraction regulates early zebrafish development {#s2-1}
------------------------------------------------------------------

To investigate how Pou5f3 controls early cell lineage differentiation in vivo, we used a phenotype complementation assay to rescue MZ *spg* mutant embryos with a GFP-Oct4 fusion protein. The GFP-Oct4 fusion protein was able to complement the *spg* phenotype in 30% of injected embryos. Because rescued embryos could only be identified from 75% epiboly onwards, we could not analyze earlier developmental events. Alternatively, morpholino (MO)-mediated knockdown of maternal Pou5f3 specifically blocks Pou5f3 activity in 100% of injected embryos, which arrest at the blastula stage ([@bib12]). This depletion approach allowed us to discriminate embryos that are rescued by the *GFP-Oct4* mRNA from those not rescued, which remained arrested at the blastula stage. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} shows the phenotypes of *pou5f3* morphants and the details of the rescue.

FCS ([Figure 1a](#fig1){ref-type="fig"}) has been previously used to study dynamic processes, such as blood flow ([@bib47]) or morphogen gradients ([@bib80]) in living zebrafish embryos. Recent studies have described the use of FCS to analyze TF protein activity in iPScells ([@bib29]) and pre-gastrula mouse embryos ([@bib24]). In cells, TFs can be found free (free fraction, F~1~) or as complexes poised to interact with DNA and regulate gene expression (bound fraction, F~2~). Using FCS ([Figure 1a](#fig1){ref-type="fig"}), we hence sought to ascertain fluctuations in the fluorescence intensity of GFP-Oct4 over a timeframe of milliseconds and calculate the autocorrelation functions (ACFs) at different developmental stages. To obtain GFP-Oct4 protein concentrations and diffusion kinetics of single cells in rescued embryos, the ACFs were fit using the two-component anomalous diffusion model (Material and methods and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). At the blastula stage (oblong stage; 3.5 hpf), the GFP-Oct4 concentration was 44.39 ± 1.54 nM ([Figure 1c--e](#fig1){ref-type="fig"} and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Non-rescued embryos arrested at the oblong stage ([Figure 1b](#fig1){ref-type="fig"}) had similar Oct4 concentrations (43.90 ± 18.30 nM) to those of rescued embryos ([Figure 1c--e](#fig1){ref-type="fig"} and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). However, the DNA-bound fraction (F~2~) was significantly lower in the non-rescued embryos (0.19 ± 0.08) as compared with the rescued ones (0.27 ± 0.01) (p\<0.0001; [Figure 1c--e](#fig1){ref-type="fig"} and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). When a construct of Oct4 lacking its homeodomain (GFP-Oct4ΔHD) was used instead, the DNA-bound fraction further decreased, and all embryos arrested at the oblong stage (0.12 ± 0.01) (p\<0.0001; [Figure 1c--e](#fig1){ref-type="fig"} and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). These results suggest that specific levels of the Oct4 DNA-bound active fraction---and, by extension, Pou5f3---are crucial for proper embryo gastrulation.10.7554/eLife.11475.003Figure 1.Oct4 DNA-bound active fraction controls zebrafish gastrulation.(**a**) Schematic diagram of fluorescence correlation spectroscopy (FCS). GFP-tagged nuclear protein is localized in the nucleus of embryonic cells. Fluorescence molecules diffuse through a confocal volume (\<1 μm^3^) within a single-cell nucleus and generate fluctuating fluorescence intensity. The autocorrelation function (ACF) of the fluctuation is fit to obtain the absolute protein concentration (C) and the diffusion coefficient (D), where N is the number of molecules. Scale bar: 10 μm. (**b**) Lateral view of *pou5f3* morphant embryos expressing GFP-Oct4 rescued by *GFP-Oct4* mRNA at the blastula \[3.5 hr post-fertilization (hpf)\] and gastrula (7 hpf) stages and non-rescued embryos (arrested) at the blastula stage. The non-rescued embryos also express GFP-Oct4 but remain at the blastula stage and do not develop further. Scale bar: 200 μm. (**c**) ACF of the intensity traces of GFP-Oct4 and GFP-Oct4ΔHD in rescued and non-rescued embryos at the blastula stage. The ACF were fit by two-component anomalous diffusion model. Curves are normalized to compare differences in protein activity (indicated by arrows). (**d**) Raw data of residuals from fit curves shown in **c**. (**e**) Concentration and DNA-bound fraction levels derived from the FCS measurements in **c**. Values represent the mean ± SEM of data from three to five independent experiments (*n *= 39--125 cell nuclei from 10 to 15 embryos *\*\*\*\**p*\<*0.0001; *\*\**p*\<*0.01). n.s. over bars indicates non-significant differences. See also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"} and Materials and methods.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.003](10.7554/eLife.11475.003)10.7554/eLife.11475.004Figure 1---source data 1.Quantification of GFP-Oct4 concentration and activity in zebrafish rescued and non-rescued embryos.Values for concentration and diffusion parameters were derived from the analysis of FCS data with the ACFs fit by two-component anomalous diffusion model. D~1~, D~2~: Diffusion coefficients of the fast and slow diffusion components, respectively. F~2~: Slow component fraction. α~1~, α~2~: anomalous parameters of the fast and slow diffusion components, respectively. Values represent mean ± SEM of data from three to five independent experiments (*n* represents the number of cell nuclei from 10 to 15 embryos; \*\*\*\*p\<0.0001; \*\*p\<0.01; \*p\<0.05). Details of the rescue and the FCS analyses are shown in [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"} and Material and methods.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.004](10.7554/eLife.11475.004)10.7554/eLife.11475.005Figure 1---figure supplement 1.GFP-Oct4 rescues zebrafish Pou5f3 function.(**a**) Phenotypes of *pou5f3* knockdown using morpholino (MO) antisense. Arrows show a constriction in the interface between the yolk and the blastoderm, prohibiting gastrulation in embryos arrested at the blastula stage after MO injection. Embryos not arrested show zygotic phenotype: they do not develop the mid--hindbrain boundary (\*MHB) at the 24-hpf stage. (**b**) Relative percentages of different phenotypes according to the dose of *pou5f3* MO injected. Phenotypes are expressed as a percent of whole (*n *= 150--400 embryos per condition). As a control, a mismatch MO sequence was injected resulting in 100% of embryos with *wt* phenotype. 100% of embryos were arrested at the blastula stage using 8 ng of MO. Lower-dosed 4-ng and 2-ng embryos continued through gastrulation but did not develop the MHB, according to the percentages shown. (**c**) Phenotypes of rescued embryos. Rescue of maternal *pou5f3* function, as shown by restoring normal gastrulation. Rescue of maternal-zygotic *pou5f3* function, as shown by MHB formation at 24 hpf. (**d** and **e**) Relative percentages of (**d**) maternal and (**e**) maternal-zygotic rescue according to different amounts of injected mRNA. Phenotypes of the rescued embryos are expressed as a percent of whole (*n *= 170--400 embryos per condition).**DOI:** [http://dx.doi.org/10.7554/eLife.11475.005](10.7554/eLife.11475.005)10.7554/eLife.11475.006Figure 1---figure supplement 2.One- and two-component anomalous diffusion model for GFP and GFP-Oct4.(**a**) Autocorrelation function (ACF) of free GFP fit by two- and one-component anomalous diffusion models. Two-component anomalous diffusion model converged to effective one-component anomalous diffusion for a real one-component system, such as free GFP. (**b**) Raw data of residuals from fit curves shown in **a**. (**c**) Quantitative parameters derived from the ACFs. F~1~: Fast component fraction. D~1~, D~2~: Diffusion coefficients of the fast and slow diffusion components, respectively. α~1,~ α~2~: anomalous parameters of the fast and slow diffusion components, respectively. I/N: Ratio of mean intensity extracted directly from the time traces and the mean number of molecules in the focus extracted from the fit, referred to as molecular brightness. *n*: number of cells. (**d**) The GFP-Oct4-free diffusion coefficient (D~1~) determined by global fitting and averaging individual fits yields provides similar diffusion time, tauD~1~. Values represent mean ± SEM of data from three independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.006](10.7554/eLife.11475.006)10.7554/eLife.11475.007Figure 1---figure supplement 3.Oct4 concentration and DNA-bound active fraction in embryos rescued with different amount of *GFP-Oct4 mRNA*.(**a**) Autocorrelation function (ACF) of the intensity traces of GFP-Oct4 by the two-component fit anomalous diffusion model in rescued embryos with different amounts of *GFP-Oct4* mRNA at blastula (oblong; 3.5 hpf) and gastrula (60% epiboly; 7 hpf) stages. Double-headed arrow in the graph indicates the difference in the amplitude of the curves, which corresponds to the difference in protein concentrations. (**b**) Raw data of residuals from fit curves shown in **a**. (**c**, **d**) Concentration (**c**) and DNA-bound fraction (**d**) derived from the FCS measurements in **a**. Changes in the GFP-Oct4 concentration at oblong stage in rescued embryos were concordant with the proportion of mRNA injected. However, the Oct4 DNA-bound fraction did not significantly change with varying concentrations. Concentration and Oct4 DNA-bound fraction remained similar in rescued embryos at 60% epiboly. Values represent mean ± SEM of data from three independent experiments (*n *\> 35 cell nuclei from 10 to 15 embryos; *\*\**p\<0.01). n.s. over bars indicates non-significant differences. See also [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.007](10.7554/eLife.11475.007)

The TFs Pou5f3 and Nanog complex in vivo in the mesendoderm lineage {#s2-2}
-------------------------------------------------------------------

We next set out to determine the tissue-specific distribution of the DNA-bound active fraction (F~2~) of Pou5f3 within a developing embryo at the blastula stage (oblong; 3.5 hpf) using GFP-Oct4. In zebrafish, unlike in mammals, it is possible to follow mesendoderm and ectoderm formation during early development ([@bib20]) ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). For that purpose, zygotes were injected with *GFP-Oct4* mRNA followed by dextran red as a lineage tracer into two central cells at the 16-cell stage, such that the dextran red-positive cells are entirely ectodermal, whereas 83.7% of the negative cells are mesendodermal ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). FCS measurements were performed for both labeled and unlabeled cells. The ACFs of the intensity traces were fit using a two-component anomalous diffusion model. Mesendodermal cells showed a significantly higher proportion of the DNA-bound active fraction of GFP-Oct4 protein as compared with ectodermal cells (0.27 ± 0.01 *vs* 0.19 ± 0.01, respectively; p\<0.0001; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). Dextran red-labeled mesendodermal cells were used as a control for the assay ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Thus, at the oblong stage, the DNA-bound active fraction of Oct4 was higher in the mesendoderm than in the ectoderm lineage.10.7554/eLife.11475.008Figure 2.Oct4 and Nanog bind in mesendoderm of zebrafish blastula embryos.(**a**) Schematic location of the presumptive mesendoderm (ME) and ectoderm (EC) in an embryo at oblong stage \[3.5 hr post-fertilization (hpf)\]. Scale bar: 200 µm. (**b**) Schematic diagram of FLIM-FRET (Fluorescence Lifetime Microscopy--Forster Resonance Energy Transfer). GFP lifetime (t1) of the donor is reduced if an acceptor (mCherry) is in close proximity (1--10 nm); this is the reduced lifetime (t2). If the acceptor is not in close proximity (\>10 nm) to the donor, donor lifetime remains unchanged (t2 similar to t1). Lifetimes are measured with time-correlated single-photon counting. (**c**) Lifetime values and FLIM images of GFP-Oct4 alone and in the presence of a linked mCherry protein in single cells. Scale bar: 10 µm. In the same graph, lifetime values and FLIM images of GFP-Oct4ΔHD alone and co-expressing mCherry-Nanog in single nuclei. Scale bar: 5 µm. (**d**) Lifetime values and FLIM images of GFP-Oct4 lifetime alone and in the presence of mCherry-Nanog in the nucleus of individual cells from mesendoderm or ectoderm. Scale bar: 5 µm. The percentage of binding is indicated at the top right corner of the FLIM images. Values represent the median and quartile ranges of data from three to five independent experiments (*n *= 20--40 cell nuclei from 10 to 15 embryos; \*\*\*\*p\<0.0001). n.s. over bars indicates non-significant differences. See also [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[4](#fig2s4){ref-type="fig"}, [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"} and [2](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.008](10.7554/eLife.11475.008)10.7554/eLife.11475.009Figure 2---source data 1.Quantification of GFP-Oct4 and GFP-Nanog activity in mesendoderm and ectoderm of *wt* and morphant zebrafish embryos.Diffusion parameters values were derived from analysis of FCS data with the ACFs fit by two-component anomalous diffusion model. D~1~, D~2~: Diffusion coefficients of the fast and slow diffusion components, respectively. F~2~: Slow component fraction. α~1~, α~2~: anomalous parameters of the fast and slow diffusion components, respectively. ME: mesendoderm. EC: ectoderm. Values represent mean ± SEM from three to five independent experiments (*n* represents the number of cell nuclei from 10 to 15 embryos; \*\*\*\*p\<0.0001; \*\*\*p\<0.001). Details of the MOs and FCS analyses are shown in [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"},[3](#fig2s3){ref-type="fig"} and Material and methods.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.009](10.7554/eLife.11475.009)10.7554/eLife.11475.010Figure 2---source data 2.FCCS parameters of GFP-Nanog and mCherry-Oct4 in mesendoderm and ectoderm of blastula embryos (oblong stage; 3.5 hpf).Diffusion parameters values were derived from analysis of FCCS data with the ACFs and CCF fit by two-component anomalous diffusion model. D~1~, D~2~: Diffusion coefficient of the fast and slow diffusion component, respectively. α~1~, α~2~: anomalous parameter of the fast and slow diffusion component, respectively. *Kd*: dissociation constant at equilibrium; values were obtained from the slopes of the fitted linear line when plotting the concentration of GFP-Nanog (C~N~) \* concentration of mCherry-Oct4 (C~O~) versus the concentration of the proteins association (C~NO~). If the proteins are associated, there will be a linear line; in cases where no association exists, there is no linear relationship (N.L). Association: fraction of proteins diffusing together in the same complex. Details of the FCCS analysis are shown in [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} and Materials and methods. ME: mesendoderm. EC: ectoderm. Values represent mean ± SEM from three to five independent experiments with *n *\> 15.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.010](10.7554/eLife.11475.010)10.7554/eLife.11475.011Figure 2---figure supplement 1.GFP-Oct4 dynamics in blastula embryos.(**a**) GFP-Oct4 expressed in the blastoderm at the blastula stage (oblong; 3.5 hpf). Ectoderm (EC) cells are traced by dextran red; non-labeled cells are mesendoderm (ME). Scale bar: 200 μm. (**b**) Cells from the blastoderm expressing GFP-Oct4. Staining as in **a**. Scale bar: 20 μm. (**c**) ACF of the intensity traces of GFP-Oct4 in EC and ME in wild-type embryos. The ACF were fit by two-component anomalous diffusion model. Curves are normalized to compare differences in protein activity. (**d**) Raw data of residuals from fit curves shown in **c**. (**e**) DNA-bound fraction derived from the previous ACFs. Values represent the mean ± SEM of data from three to five independent experiments (*n *\> 60 cell nuclei from 10 to 15 embryos; \*\*\*\*p\<0.0001). (**f**) ACF of the intensity traces of GFP-Oct4 in *nanog* morphant embryos. The ACF were fit by two-component anomalous diffusion model. Curves are normalized to compare differences in protein activity. (**g**) Raw data of residuals from fit curves shown in **f**. (**h**) DNA-bound fraction derived from the previous ACFs. Values represent the mean ± SEM of data from three to five independent experiments (*n *\> 60 cell nuclei from 10 to 15 embryos; \*\*\*p\<0.001). See also [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}**DOI:** [http://dx.doi.org/10.7554/eLife.11475.011](10.7554/eLife.11475.011)10.7554/eLife.11475.012Figure 2---figure supplement 2.Dextran red does not interfere in the FCS measurements.(**a**) Embryo (oblong stage; 3.5 hpf) showing mesendoderm (ME) labeled by dextran (red) leaving the ectoderm (EC) unlabeled. Scale bar: 200 µm. (**b**) ACF of the intensity traces of GFP-Oct4 in ME cells labeled or unlabeled. FCS data were fit by two-component anomalous diffusion model. (**c**) Raw data of residuals from fit curves shown in **b**. (**d**) DNA-bound fraction and diffusion coefficient derived from the FCS measurements in **b**. Values represent mean ± SEM of data from three independent experiments (*n *= 40--100 cell nuclei from 10 to 15 embryos). n.s. over bars indicates non-significant differences.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.012](10.7554/eLife.11475.012)10.7554/eLife.11475.013Figure 2---figure supplement 3.GFP-Nanog dynamics in blastula embryos.(**a**) Cells from the blastoderm (oblong stage; 3.5 hpf) expressing GFP-Nanog. Ectoderm (EC) cells are positive for dextran red; mesendoderm (ME) cells are negative. Scale bar: 20 μm. (**b**) ACF of the intensity traces of GFP-Nanog in EC and ME in wild-type embryos. The ACF were fit by two-component anomalous diffusion model. Curves are normalized to compare differences in protein activity. (**c**) Raw data of residuals from fit curves shown in **b**. (**d**) DNA-bound fraction derived from the previous ACFs. Values represent the mean ± SEM of data from three to five independent experiments (*n *\> 60 cell nuclei from 10 to 15 embryos; \*\*\*\*p\<0.0001). (**e**) ACF of the intensity traces of GFP-Nanog in EC and ME in *pou5f3* morphant embryos. The ACF were fit by two-component anomalous diffusion model. Curves are normalized to compare differences in protein activity. (**f**) Raw data of residuals from fit curves shown in e. (**g**) DNA-bound fraction derived from the previous ACFs. Values represent the mean ± SEM of data from three to five independent experiments (*n *\> 60 cell nuclei from 10 to 15 embryos; \*\*\*p\<0.001). See also [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.013](10.7554/eLife.11475.013)10.7554/eLife.11475.014Figure 2---figure supplement 4.Oct4 and Nanog cross-correlate in mesendoderm of blastula embryos.(**a**) Schematic diagram of a setup for fluorescence cross-correlation spectroscopy (FCCS). GFP- and mCherry-tagged nuclear proteins diffuse through a confocal volume (\<1 μm^3^) within a single-cell nucleus and generate fluctuating fluorescence intensities. The autocorrelation functions (ACFs) and the cross-correlation function (CCF) of the fluctuations are fit to obtain the absolute protein concentration (**C**) and the diffusion coefficient (**D**), where N is the number of molecules. CCF is shown in black. (**b**) ACFs and CCFs of the intensity traces of GFP-Nanog co-expressed with mCherry-Oct4 in mesendoderm and ectodermal cells of blastula embryos (oblong stage; 3.5 hpf) fit by two-component anomalous diffusion model. (**c**) Raw data of residuals from fit curves shown in **b**. (**d**) *Kd* plots for GFP-Nanog and mCherry-Oct4 associations. *Kd* values were obtained from the slopes of the fitted linear line. If the proteins are associated, there will be a linear line when plotting the concentration of GFP-Nanog (C~N~) \* concentration of mCherry-Oct4 (C~O~) *versus* the concentration of the protein association (C~NO~), since *Kd* represents the constant of the association at equilibrium. There is no linear relationship in cases where there is no association. (**e**) *Kd* plots for GFP co-expressed with mCherry protein (negative control) and GFP-mCherry linked protein (tandem; positive control). Values for GFP and mCherry proteins could not be linearly fitted. Association: fraction of proteins diffusing together in the same complex. See also [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.014](10.7554/eLife.11475.014)

Next, the GFP-Oct4 DNA-bound active fraction was studied in mesendoderm of *nanog* morphants at the same stage (oblong; 3.5 hpf). A low dose of *nanog* MO, which did not cause severe developmental defects, was co-injected with *GFP-Oct4* mRNA. This co-injection led to a reduction in the bound fraction of GFP-Oct4 from 0.27 ± 0.01 to 0.22 ± 0.01 (p\<0.001; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). As a control, we carried out the reverse experiment to assess the GFP-Nanog DNA-bound active fraction in *pou5f3* morphants, measuring a reduction from 0.21 ± 0.01 to 0.16 ± 0.01 (p\<0.001; [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} and [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}). These FCS data suggest that the Pou5f3- and Nanog-binding fractions are dependent on each other in mesendoderm lineage.

Since Oct4 and Nanog share many genomic binding sites ([@bib33]; [@bib71]), we next investigated whether they interact in vivo in a cell lineage-dependent manner. We used FCCS (Fluorescence Cross-Correlation Spectroscopy; [@bib7]; [@bib28]) to study the diffusion of both proteins simultaneously in mesendoderm and ectoderm at the oblong stage (3.5 hpf; [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} and [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}). The cross-correlation function indicates whether GFP-Oct4 and mCherry-Nanog diffuse together within the same complex, and by calculating the dissociation protein constants (*Kd*), we can then determine the binding affinity of GFP-Oct4 and mCherry-Nanog. We measured a *Kd* of 15.34 ± 1.6 nM and 61.9 ± 7.5 nM in the mesendoderm and ectoderm, respectively, suggesting higher binding affinity in mesendoderm at the oblong stage ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"} and [Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"}).

To confirm the interaction of Oct4 and Nanog in a cell-lineage dependent manner, we next used FLIM-FRET (Fluorescence Lifetime Imaging Microscopy--Förster Resonance Energy Transfer) in single cells of the developing embryo. FLIM follows the lifetime of the excited state of fluorescent molecules and can be used to monitor protein--protein interactions via FRET ([@bib64]; [@bib35]) ([Figure 2b](#fig2){ref-type="fig"}). The proximity of a GFP fusion protein as a donor and an mCherry fusion protein as an acceptor reduces the lifetime of the donor, indicating a protein--protein interaction. Contrarily, no change in the lifetime indicates that the proteins are not interacting ([Figure 2b](#fig2){ref-type="fig"}). We have previously shown that Oct4 interacts with Sox2 in ESCs and iPSCs using this method ([@bib29]). Here, we used a GFP-mCherry tandem protein as a positive control to document the decrease in GFP lifetime when it interacts with mCherry as compared to the lifetime of GFP alone in zebrafish embryos (p\<0.0001; [Figure 2c](#fig2){ref-type="fig"}). *mCherry-Nanog* mRNA, co-injected with *GFP-Oct4ΔHD mRNA* was used as negative control, because the DNA binding domain of Oct4 is needed for its interaction with Nanog and, therefore, the GFP-Oct4ΔHD lifetime should not change in the presence of mCherry-Nanog ([Figure 2c](#fig2){ref-type="fig"}).

In the nuclei of individual cells within the mesendoderm and ectoderm of oblong stage embryos (3.5 hpf; [Figure 2d](#fig2){ref-type="fig"}), we found a significant reduction in the GFP-Oct4 lifetime in the presence of mCherry-Nanog in the mesendoderm (1.79 ± 0.05 ns; p\<0.0001) but not in the ectoderm (2.28 ± 0.01 ns; [Figure 2d](#fig2){ref-type="fig"}) as compared with the GFP-Oct4 lifetime in the absence of mCherry-Nanog (2.30 ± 0.01 ns; [Figure 2d](#fig2){ref-type="fig"}); the binding percentages ([@bib45]) in the mesendoderm and ectoderm were 27% and 2.2%, respectively ([Figure 2d](#fig2){ref-type="fig"}). These FLIM-FRET results demonstrate a higher proportion of Oct4--Nanog complexes in the mesendoderm as compared with that in ectoderm at the oblong stage and suggest that Pou5f3 and Nanog co-regulate mesendoderm targets during gastrulation.

Pou5f3--Nanog complexes are restricted to ventrolateral mesendoderm {#s2-3}
-------------------------------------------------------------------

Given the proportion of complexes in the oblong stage, we next sought to investigate the spatial localization of Oct4--Nanog complexes in ventral, lateral and dorsal ectoderm and mesendoderm at the 50% epiboly stage (germ ring; 5.7 hpf). This time we used FCCS to explore the diffusion of GFP-Nanog and mCherry-Oct4 and their binding affinities in the different ectodermal and mesendodermal areas. At 50% epiboly, the high *Kd* value indicated a low-binding affinity between Oct4 and Nanog in the ventrolateral ectodermal cells (*Kd*: 57.09 ± 7.06 nM), and almost a complete absence of cross-correlation in the dorsal ectoderm (*Kd*: 201 ± 49.4 nM) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}). In contrast, the *Kd* values in the ventral and lateral mesendoderm (5.4 ± 0.4 nM and 11.1 ± 0.73 nM, respectively) indicated a high-binding affinity in these regions as compared with that in the dorsal mesendoderm (36.8 ± 3.5 nM) ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) and [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}). We further confirmed these mesendodermal interactions using FLIM-FRET. We found that the GFP-Oct4 lifetime was significantly reduced in the presence of mCherry-Nanog in the ventral and lateral mesendoderm (2.29 ± 0.01 ns in absence of mCherry-Nanog to 2.02 ± 0.01 ns and 2.03 ± 0.02 ns, respectively; p\<0.0001; [Figure 3b](#fig3){ref-type="fig"}) but not in dorsal mesendoderm (2.31 ± 0.01 ns; [Figure 3b](#fig3){ref-type="fig"}). The percentage of binding was greater than 20% in the ventral and lateral mesendoderm but only 4.7% in the dorsal area ([Figure 3b](#fig3){ref-type="fig"}).10.7554/eLife.11475.015Figure 3.Oct4 and Nanog complexes in the ventrolateral mesendoderm.(**a**) *wt* embryo showing the ventral (V)--lateral (L)- and dorsal (D)-mesendoderm (ME) at the 50% epiboly \[5.7 hr post-fertilization (hpf)\] before commencement of involution. LiCl-dorsalized embryo at 5.7 hpf. Arrows show the dorsal organizer of the *wt* embryo and radialized dorsal structures along the germ ring of dorsalized embryos. Scale bar: 200 µm (**b**) Lifetime values and FLIM images of GFP-Oct4 lifetime alone and in the presence of mCherry-Nanog in the nuclei of individual cells measured at different locations within the mesendoderm. Values represent the median and quartile ranges of data from three to five independent experiments (*n *= 30--70 cell nuclei from 10 to 15 embryos; *\*\*\*\**p\<0.0001). The percentage of binding is indicated at the top right corner of the FLIM images. Scale bar: 5 µm. n.s. over bars indicates non-significant differences. See also [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"},[2](#fig3s2){ref-type="fig"} and [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.015](10.7554/eLife.11475.015)10.7554/eLife.11475.016Figure 3---source data 1.FCCS parameters of GFP-Nanog and mCherry-Oct4 in mesendoderm and ectoderm of gastrula embryos (50% epiboly; 5.7 hpf).Diffusion parameters were derived from analysis of FCCS data with the ACFs and CCF fit by two-component anomalous diffusion model. D~1~, D~2~: Diffusion coefficients of the fast and slow diffusion components, respectively. α~1~, α~2~: anomalous parameters of the fast and slow diffusion components, respectively. *Kd*: dissociation constant at equilibrium; values were obtained from the slopes of the fitted linear line when plotting the concentration of GFP-Nanog (C~N~) \* concentration of mCherry-Oct4 (C~O~) *versus* the concentration of the proteins association (C~NO~). If the proteins are associated, there will be a linear line; in cases where no association exists, there is no linear relationship. Association: fraction of proteins diffusing together in the same complex. Details of the FCCS analysis are explained in the Materials and methods. V-ME: ventral mesendoderm; ME: lateral mesendoderm; D-ME: dorsal mesendoderm; V-EC: ventral ectoderm; D-EC: dorsal ectoderm. Values represent mean ± SEM from three to five independent experiments with *n *\> 15.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.016](10.7554/eLife.11475.016)10.7554/eLife.11475.017Figure 3---figure supplement 1.Nanog and Oct4 cross-correlation in the ectoderm of gastrula embryos.(**a**) ACFs and CCFs of the intensity traces of GFP-Nanog co-expressed with mCherry-Oct4 in ectoderm (EC) cells of gastrula (50% epiboly; 5.7 hpf) embryos fit by two-component anomalous diffusion model. (**b**) Raw data of residuals from fit curves shown in **a**. (**c**) *Kd* plots for GFP-Nanog and mCherry-Oct4 associations. *Kd* values were obtained from the slopes of the fitted linear line. If the proteins are associated, there will be a linear line when plotting the concentration of GFP-Nanog (C~N~) \* concentration of mCherry-Oct4 (C~O~) *versus* the concentration of the protein association (C~NO~), since *Kd* represents the constant of the association at equilibrium. There is no linear relationship in cases where there is no association. Association: fraction of proteins diffusing together in the same complex. See also [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}**DOI:** [http://dx.doi.org/10.7554/eLife.11475.017](10.7554/eLife.11475.017)10.7554/eLife.11475.018Figure 3---figure supplement 2.Nanog and Oct4 cross-correlation in ventrolateral mesendoderm of gastrula embryos.(**a**) ACFs and CCFs of the intensity traces of GFP-Nanog co-expressed with mCherry-Oct4 in ventral, lateral and dorsal mesendoderm (ME) cells of gastrula embryos (50% epiboly; 5.7 hpf) fit by two-component anomalous diffusion model. (**b**) Raw data of residuals from fit curves shown in **a**. (**c**) *Kd* plots for GFP-Nanog and mCherry-Oct4 associations. *Kd* values were obtained from the slopes of the fitted linear line. If the proteins are associated, there will be a linear line when plotting the concentration of GFP-Nanog (C~N~) \* concentration of mCherry-Oct4 (C~O~) *versus* the concentration of the protein association (C~NO~), since *Kd* represents the constant of the association at equilibrium. There is no linear relationship in cases where there is no association. Association: fraction of proteins diffusing together in the same complex. See also [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.018](10.7554/eLife.11475.018)

Finally, we used LiCl treatment, which activates Wnt/β-catenin signaling ([@bib61]), to assess the distribution of Oct4--Nanog complexes in dorsalized embryos. Embryos at the 32-cell stage were treated with LiCl and monitored for changes in Oct4--Nanog complexes using FLIM-FRET. As expected, LiCl-treated embryos exhibited radialized dorsal structures along the germ ring ([Figure 3b](#fig3){ref-type="fig"}). The cells from these radial dorsal structures showed a similar percentage of Oct4--Nanog binding to that of cells from the dorsal mesendoderm of non-treated embryos (2% and 4.7%, respectively; [Figure 3b](#fig3){ref-type="fig"}). These results suggest that uneven yet specific levels of the Pou5f3--Nanog complex may drive DV mesendodermal patterning.

Nanog cooperates with Pou5f3 to promote ventral fate {#s2-4}
----------------------------------------------------

Pou5f3 is known to act in DV patterning ([@bib54]). To address whether Nanog is involved with Pou5f3 in driving DV patterning, we performed a series of Nanog loss-of-function experiments using varying amounts of *nanog* MO ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). With 1.6 ng of *nanog* MO, we observed that 90% of morphants were Class (C) IV (poorly developed axial structures, and no apparent eyes, trunk or tail) ([Figure 4a,b](#fig4){ref-type="fig"}); with 0.4 ng of *nanog* MO, 70% of morphants showed C III (truncated bodies and hypoplastic eyes) and C II phenotypes (normal head structures, a short body axis, a bent tail and no fins) ([Figure 4a,b](#fig4){ref-type="fig"}). Near complete rescue (C I) was observed when 0.1 ng of *nanog* mRNA (lacking the MO-target site) was co-injected with 0.4 ng of MO ([Figure 4a,b](#fig4){ref-type="fig"}). Embryos injected with *nanog* mismatch-MO (5 mismatch nucleotides; *nanog\**) developed normally (data not shown).10.7554/eLife.11475.019Figure 4.Pou5f3 and Nanog promote ventral fate.(**a**) *nanog* MO-injected larvae show severely affected (Class (C) IV), less-severely affected (C III), mildly affected (C II) and least affected (C I) phenotypes. (**b**) Relative percentages of C I, C II, C III and C IV larvae according to dose of *nanog* MO injected (1.6 ng of *nanog* MO injection, *n *= 167; 0.8 ng of *nanog* MO injection, *n *= 186; 0.4 ng of *nanog* MO injection, *n *= 143). Co-injection of *nanog* MO (0.4 ng) with *nanog*\* mRNA (0.1 ng) leads to over 80% *wt*-like larvae as opposed to 20% wt-like larvae in its absence (*n *= 126). (**c--e**) Embryos are at 50%-epiboly except where indicated. Embryos are in top views except lateral views for *bmp2b-, oct4-* and *sox17*-stained embryos. Dorsal is to the right-hand side. Markers were analysed following injection of 0.8 ng of *nanog* MO at the 1-cell stage. (**c**) *chd* expression in the dorsal margin is expanded ventrally in 30%-epiboly *nanog* morphants relative to *wt* embryos (86%, *n *= 40), and is uniformly expressed in the blastoderm of *nanog* morphants at 50%-epiboly relative to *wt* embryos (94%, *n *= 66). *gsc* expression in the prospective shield is expanded ventrally within the germ ring in *nanog* morphants relative to *wt* embryos at the early gastrula stage (71%, *n *= 47). *bmp2b* expression in the ventral ectoderm and organizer is markedly reduced in *nanog* morphants relative to *wt* embryos at mid-gastrulation (96%, *n *= 45). Expression of *vox,* a BMP target, is greatly diminished in *nanog* morphants relative to *wt* embryos (86%, *n *= 68). Expression of *vent* in the ventral margin is nearly absent in *nanog* morphants relative to *wt* embryos (95%, *n *= 56). At the early-gastrula stage, *pou5f3* expression in the blastoderm is reduced in *nanog* morphants compared to *wt* embryos (97%, *n *= 44). (**d**) Effect of MZ*spg, nanog* MO and MZ*spg/nanog* MO on the expression of *chd* and *vox. chd* expression in the organizer of *wt* embryos (100%, *n *= 92) is ventrally expanded in MZ*spg* embryos (98%, *n *= 75) and *nanog* morphants (90%, *n *= 97). In *nanog* MO-injected MZ*spg* embryos, *chd* expression is further expanded in the entire blastoderm (92%, *n *= 62). *vox* expression in the ventral margin of *wt* embryos (100%, *n *= 96) is markedly reduced in MZ*spg* embryos (97%, *n *= 60) and *nanog* morphants (88%, *n *= 84). In *nanog* MO-injected MZ*spg* embryos, *vox* expression is completely lost (94%, *n *= 58). (**e**) Effect of *oct4* mRNA in *nanog* MO, and *nanog* mRNA in MZ*spg* mutant on *chd* expression. *chd* expression is ventrally expanded in MZ*spg* embryos (98%, *n *= 75) relative to *wt* embryos (100%, *n *= 92). *nanog* mRNA cannot cause *chd* expansion when injected into *wt* embryos (93%, *n *= 65) and cannot rescue *chd* ventral expansion when injected into MZ*spg* embryos (94%, *n *= 52). *chd* expression is ventrally expanded in *nanog* morphants (90%, *n *= 97) relative to *wt* embryos (100%, *n *= 92). *Pou5f3* mRNA cannot cause *chd* expansion when injected into *wt* embryos (92%, *n *= 67) and cannot rescue *chd* ventral expansion caused by *nanog* depletion when co-injected with *nanog* MO (88%, *n *= 64). Data are from three to five independent experiments (*n *= 40--150). See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.019](10.7554/eLife.11475.019)10.7554/eLife.11475.020Figure 4---figure supplement 1.*Nanog* controls dorsoventral (DV) patterning.(**a**) Maternal *nanog* mRNA is ubiquitously expressed in each blastomere of the eight-cell stage embryo. After mid-blastula transition*, nanog* expression is uniform in the blastoderm at the dome stage. At 50% epiboly, *nanog* mRNA is detected in all cells of the blastoderm. *nanog* mRNA accumulation is minimal by 100% epiboly. At 1 day, *nanog* transcripts are no longer detected. (**b**) Position of the nanog ATG-blocking morpholino relative to the translation initiation start of the zebrafish *nanog* allele. (**c**) RT-PCR analysis shows that, relative to *actin, nanog* expression in the developing embryo lasts until the onset of neurulation at early gastrulation, with high maternal contribution in oocytes. (**d**) qRT-PCR analysis reveals that *nanog* depletion or overexpression differentially affects the transcription of selected marker genes. Values represent mean ± SE of data from three independent experiments; p\<0.01 except for *cyclinB1*. (**e**) *nanog* morphants, relative to *wt* embryos, lack non-neural ectoderm, as documented by the absence of *gata2* expression at the end of gastrulation (88%, *n *= 52). Similarly, expression of *dlx3* is lost in *nanog* morphants relative to *wt* embryos (85%, *n *= 48). Expression of the forebrain--midbrain marker *otx2* is radialized in *nanog* morphants at 100% epiboly relative to *wt* embryos (95%, *n *= 41). *ntl* expression in the dorsal midline and *myoD* in the somites are mis-localized and absent, respectively, in *nanog* morphants relative to *wt* embryos at the 8--10 somite stage (97%, *n *= 52). The endoderm marker *sox17* is dramatically reduced in *nanog* morphants relative to *wt* embryos at the mid-gastrula stage (92%, *n *= 65). *sqt* expression in the blastoderm margin at 30% epiboly is markedly reduced in *nanog* morphants relative to *wt* embryos (94%, *n *= 39). Presumptive segmental plate expression of *her1* at the 1--4 somite stage is lost in *nanog* morphants relative to *wt* embryos (95%, *n *= 45). The ventrolateral mesoderm markers *eve1* and *tbx6* are reduced and absent, respectively, in *nanog* morphants relative to *wt* at 50% epiboly (97%, *n *= 25; 100%, *n *= 25).**DOI:** [http://dx.doi.org/10.7554/eLife.11475.020](10.7554/eLife.11475.020)

We further analyzed the specification of the DV axis, which is driven by a gradient of BMP activity, by measuring the expression of specific markers. In particular, the expression of *chd* at the dorsal pole was up-regulated dramatically: at the 30% epiboly stage, *chd* was expressed circumferentially, whereas at 50% epiboly, *chd* transcripts were ubiquitous ([Figure 4c](#fig4){ref-type="fig"}). *gsc*, a dorsally expressed gene primarily controlled by the Nodal pathway, was also up-regulated but to a lesser extent, suggesting that Nanog largely controls the levels of BMP signaling ([Figure 4c](#fig4){ref-type="fig"}). Whereas *bmp2b* expression was localized at the embryonic shield and broadly expressed ventrally at the 70% epiboly stage in controls, *nanog* morphants showed significantly down-regulated *bmp4* (data not shown) and *bmp2b* expression ([Figure 4c](#fig4){ref-type="fig"}). Consistently, the expression of direct targets of BMP signaling, such as *vox* and *vent*, was greatly reduced in *nanog* morphants at the 50% epiboly stage ([Figure 4c](#fig4){ref-type="fig"}). The spatial distribution of *pou5f3* transcripts in *nanog* morphants during 50% epiboly was not affected, but the level of expression was reduced ([Figure 4c](#fig4){ref-type="fig"}). Together, these results indicate that *nanog* knockdown leads to the dorsalization of embryos and that maternal *nanog* activity is necessary for ventral cell specification by BMPs.

The dorsalization and loss of endoderm in *nanog* morphants is reminiscent of the phenotype of MZ*spg* mutants, which are completely devoid of Pou5f3 ([@bib34]; [@bib54]). This supports and reinforces the idea that Pou5f3 and Nanog may participate in the same developmental program. To test this, MZ*spg* mutants and *nanog* morphants were compared with embryos deficient in both MZ*spg* and *nanog* using markers of DV patterning. Expansion of the dorsal marker, *chd*, was more pronounced in MZ*spg/nanog*-deficient embryos as compared with *nanog* morphants or MZ*spg* mutants at the 50% epiboly stage ([Figure 4d](#fig4){ref-type="fig"}). Conversely, the ventral marker, *vox*, was absent in MZ*spg/nanog*-deficient embryos but only reduced in both *nanog* morphants and MZspg mutants ([Figure 4d](#fig4){ref-type="fig"}). Lastly, we tested if *nanog* overexpression could compensate for the loss of *pou5f3* or if *pou5f3* could compensate for the depletion of *nanog*. Injection of *nanog* mRNA into MZ*spg* mutants failed to rescue the expression of *chd* ([Figure 4e](#fig4){ref-type="fig"}). Similarly, injection of *pou5f3* mRNA into *nanog* morphants could not rescue DV patterning ([Figure 4e](#fig4){ref-type="fig"}). These results suggest that *pou5f3* and *nanog* display overlapping functions during DV patterning but cannot compensate for one another. This is consistent with the notion that Nanog must cooperate with Pou5f3 to promote ventral fate.

Sox32 modulates Pou5f3--Nanog complexes to specify mesendoderm along the DV axis {#s2-5}
--------------------------------------------------------------------------------

The paucity of Oct4--Nanog complexes in the dorsal mesendoderm at 50% epiboly suggested that some other TFs could partner with Oct4 to replace Nanog. Lineage tracing experiments have shown that dorsal endodermal precursors arise from cells in the dorsal mesendoderm near the margin before the cells involute to form the hipoblast, and that those situated above are restricted to the mesoderm ([@bib74]). The dorsal side is easily detected by the presence of the 'shield' at 50% epiboly, but the ventrolateral endodermal cells are derived from dispersed precursors located close to the margin, which makes them impossible to distinguish morphologically at this stage. Previously, we have shown that Oct4 and Nanog form complexes in the whole mesendoderm at 3.5 hpf and, by 4 hpf, Sox32 expression starts in the dorsal endodermal cells and extends to ventrolateral endoderm ([@bib66]). Thus, we next tested whether Sox32 could compete with Nanog for Oct4 binding in the prospective dorsal endoderm.

In *sox32* morphants, we saw a significant reduction in the lifetime of GFP-Oct4 in the presence of mCherry-Nanog (2.31 ± 0.01 ns to 2.16 ± 0.03 ns, p\<0.0001; [Figure 5a-c](#fig5){ref-type="fig"}), and an increase in the binding percentage from 1% to 15%, indicating that the Oct4--Nanog complex forms in the absence of Sox32 in the dorsal endoderm precursors at 50% epiboly ([Figure 5a-c](#fig5){ref-type="fig"}). To verify the existence of Oct4--Sox32 complexes in these cells in vivo, we followed the GFP-Sox32 lifetime in the presence and absence of mCherry-Oct4. We found that the GFP-Sox32 lifetime was significantly reduced from 2.54 ± 0.01 ns in the absence of mCherry-Oct4 to 2.21 ± 0.04 ns in presence of mCherry-Oct4, with a binding percentage of 18% (p\<0.0001; [Figure 5a-c](#fig5){ref-type="fig"}). [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} and [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"} show that Nanog also interacts with Sox32 in the dorsal endoderm at 50% epiboly. The co-existence of these Oct4--Sox32 and Nanog--Sox32 complexes was further confirmed in ventrolateral endodermal cells at 60% epiboly (7 hpf) using the Tg(*sox17*:GFP-UTRN) line, which reports *sox17* promoter activity by driving *actin*-GFP ([@bib78]) ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Together, these results suggest that Sox32 prevents the formation of Pou5f3--Nanog complexes at the 50% epiboly stage in dorsal aspects and restricts them to the ventrolateral mesendoderm.10.7554/eLife.11475.021Figure 5.Sox32 competes with Nanog for Oct4 binding at dorsal endoderm of gastrula embryos.(**a**) The schematic shows the main germ layers of the embryo at 50% epiboly (5.7 hpf) with ectoderm in blue and mesendoderm in green. The dorsal-restricted endoderm precursors are shown in yellow. (**b**, **c**) Lifetime values (**b**) and FLIM images (**c**) of GFP-Sox32 and GFP-Oct4 alone and in the presence of mCherry-Oct4 and mCherry-Nanog, respectively, in the nuclei of individual cells of dorsal endoderm precursors. Scale bar: 5 µm values represent the median and quartile ranges of data from three to five independent experiments (*n *= 20--30 cell nuclei from 10 embryos; *\*\*\*\**p\<0.0001). See also [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.021](10.7554/eLife.11475.021)10.7554/eLife.11475.022Figure 5---source data 1.FCCS parameters of GFP-Sox32 and mCherry-Nanog in endoderm of gastrula embryos (50% epiboly; 5.7 hpf).Diffusion parameters were derived from analysis of FCCS data with the ACFs and CCF fit by two-component anomalous diffusion model. D~1~, D~2~: Diffusion coefficients of the fast and slow diffusion components, respectively. α~1~, α~2~: anomalous parameters of the fast and slow diffusion components, respectively. *Kd*: dissociation constant at equilibrium; values were obtained from the slopes of the fitted linear line when plotting the concentration of GFP-Sox32 (C~S~) \* concentration of mCherry-Nanog (C~N~) *versus* the concentration of the proteins association (C~SN~). If the proteins are associated, there will be a linear line; in cases where no association exists, there is no linear relationship. Association: fraction of proteins diffusing together in the same complex. Details of the FCCS analysis are explained in the Materials and methods. D-E: dorsal endoderm; V-E: ventral endoderm; Values represent mean ± SEM from three to five independent experiments with *n *\> 15.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.022](10.7554/eLife.11475.022)10.7554/eLife.11475.023Figure 5---figure supplement 1.Sox32 binds Oct4 in ventrolateral endoderm.Lifetime values of GFP-Sox32 lifetime alone and co-expressed with mCherry-Oct4 in the nuclei of individual cells from the row next to the margin in ventrolateral mesendoderm at 50% epiboly (5.7 hpf) before involution starts. Those showing a decrease in the lifetime are endoderm precursors and those with similar lifetime are mesoderm precursors. (**b**) GFP-Sox32 and mCherry-Oct4 co-expressed in Tg(*sox17*:GFP-UTRN) embryos at 60% epiboly (7 hpf). Scale bar: 20 μm. (**c**) Lifetime values and FLIM images of GFP-Sox32 lifetime alone and co-expressed with mCherry-Oct4 in the nuclei of individual cells in ventrolateral endoderm at 60% epiboly (7 hpf). The percentage of binding is indicated at the top right corner of the FLIM image. Values represent the median and quartile ranges of data from three independent experiments (*n *= 20--30 cell nuclei from 10 embryos; *\*\*\*\**p\<0.0001). Scale bar: 5 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.023](10.7554/eLife.11475.023)10.7554/eLife.11475.024Figure 5---figure supplement 2.Nanog and Sox32 interact in endoderm.(**a**, **b**) ACFs and CCFs of the intensity traces of GFP-Sox32 co-expressed with mCherry-Nanog in (**a**) the dorsal endoderm precursors at 50% epiboly (5.7 hpf) and (**b**) in ventrolateral endoderm cells in Tg(*sox17*:GFP-UTRN) embryos at 60% epiboly (7 hpf) fit by two-component anomalous diffusion model. (**c**, **d**) Raw data of residuals from fit curves shown in **a**, **b**, respectively. (**e**) *Kd* plots for GFP-Sox32 and mCherry-Nanog associations. *Kd* values were obtained from the slopes of the fitted linear line. If the proteins are associated, there will be a linear line when plotting the concentration of GFP-Sox32 (C~S~) \* concentration of mCherry-Nanog (C~N~) *versus* the concentration of the protein association (C~SN~), since *Kd* represents the constant of the association at equilibrium. There is no linear relationship in cases where there is no association. Association: fraction of proteins diffusing together in the same complex. (**f**) Lifetime values of GFP-Sox32 lifetime alone and co-expressed with mCherry-Nanog in the nuclei of individual cells of dorsal and ventrolateral endoderm at the stages previously described. Values represent the median and quartile ranges of data from three independent experiments (*n *= 20--30 cell nuclei from 10 embryos; *\*\**p\<0.01; *\*\*\**p\<0.001). See also [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.024](10.7554/eLife.11475.024)

To ascertain whether Oct4 and Nanog still bind in ventrolateral mesoderm and endoderm lineages at 60% epiboly (7 hpf; ([Figure 6a--c](#fig6){ref-type="fig"}), we measured the GFP-Oct4 lifetime in the absence and presence of mCherry-Nanog. We observed a significant reduction in GFP-Oct4 lifetime from 2.31 ± 0.01 ns to 2.01 ± 0.02 ns and 1.98 ± 0.02 ns in the ventrolateral mesoderm and endoderm, respectively (p\<0.0001; ([Figure 6a--c](#fig6){ref-type="fig"}), suggesting that Pou5f3--Nanog complexes may be involved in ventrolateral patterning at later stages.10.7554/eLife.11475.025Figure 6.Sox32 modulates Oct4 and Nanog complexes in ventrolateral endoderm of gastrula embryos.(**a**) The schematic shows the Ventrolateral (VL)- and dorsal (D)-mesendoderm layers at 60% epiboly (7 hpf), with mesoderm in orange and endoderm in yellow. (**b**, **c**) Lifetime values (**b**) and FLIM images (**c**) of GFP-Oct4 alone and in the presence of mCherry-Nanog in the nuclei of individual cells within VL-Mesoderm and VL-Endoderm cells of *wt* and *ela^br13 ^*mutants. Values of FLIM data represent the median and quartile ranges of data from three to five independent experiments (*n *= 20--40 cell nuclei from 10 embryos; \*\*\*p\<0.0001). Scale bar: 5 µm. (**d**) qRT-PCR analysis of *sox32* relative to *actin* in *wt* and *ela^br13^* mutant embryos. Values represent mean ± SEM of data from three independent experiments (\*\*p\<0.01). (**e**) Graphs show percentage of binding of GFP-Oct4 and mCherry-Nanog in VL-Mesoderm and VL-Endoderm of *wt* and *ela^br13 ^*mutant embryos. Values represent the median and quartile ranges from data of three to five independent experiments (*n *= 20--40 cell nuclei from 7 to 10 embryos; \*\*p\<0.01). Values represent mean ± SEM of data from three independent experiments (*\*\**p\<0.01). n.s. over bars indicates non-significant differences. (**f**) qRT-PCR analysis relative to *actin* reveals different transcription levels of *bmp2b, bmp4, bmp2a* and *her5* in *ela^br13^* mutants at 60% epiboly (7 hpf). Values represent mean ± SEM of data from three independent experiments (*\*\**p\<0.01). (**g**) *bmp4* expression (top view, dorsal is to the right-hand side) is ventrally reduced in *ela^br13^* mutants compared with *wt* embryos. *her5* expression (dorsal view) is dorsally upregulated in *ela^br13^* mutants related to *wt* embryos. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.025](10.7554/eLife.11475.025)10.7554/eLife.11475.026Figure 6---figure supplement 1.Ela/Aplnr pathway refines ventrolateral Bmp signaling.Expression of the ventrolateral mesoderm markers, *tbx6* and *eve1*, was slightly down-regulated in ela*^br13^* relative to *wt* embryos at 50% epiboly. *Chd* expression in the dorsal margin and *gsc* in the prospective shield does not change in ela*^br13^*ascompared with *wt* embryos at 50% epiboly. Ectoderm markers, gata2 (non-neural ectoderm) and otx2 (forebrain-midbrain), remained similar in ela*^br13^* relative to *wt* embryos at 75% epiboly.**DOI:** [http://dx.doi.org/10.7554/eLife.11475.026](10.7554/eLife.11475.026)

Elabela mutant (*ela^br13^*) embryos have a significantly lower number of endodermal progenitors that express *sox17*; yet, the total levels of *sox17* are still higher in *ela^br13^*embryos than in control siblings ([@bib15]). Likewise, *sox32* levels are higher in *ela^br13^*embryos than in control siblings (p\<0.01; [Figure 6d](#fig6){ref-type="fig"}). To gain insight into this conundrum, we next followed Oct4--Nanog complexes in ventrolateral mesodermal and endodermal cells of Tg (*sox17*:GFP-UTRN; *ela^br13^*) embryos. We observed a significant decrease in the GFP-Oct4 lifetime, suggesting that Pou5f3 and Nanog also interact in the ventrolateral mesoderm and endoderm of *ela^br13^* embryos ([Figure 6b](#fig6){ref-type="fig"}). Interestingly, in contrast to mesodermal cells, the percentage of Oct4--Nanog complexes in endodermal cells was significantly reduced from 21% to 15% (p\<0.01; [Figure 6e](#fig6){ref-type="fig"}). These results support the idea that Sox32 competes with Nanog for Pou5f3 binding to regulate cell fate.

Next, we tested whether the decrease in the percentage of Oct4--Nanog complexes in ventrolateral endoderm of *ela^br13 ^*embryos would affect BMP signaling. We found that *bmp4* expression was more reduced and restricted to the ventral area of *ela^br13 ^*embryos. *bmp2b* and *bmp2a* expression was also lower in *ela^br13 ^*embryos as compared to *wt* embryos ([Figure 6f](#fig6){ref-type="fig"}). The expression of ventrolateral mesoderm *bmp* targets, such as *tbx6* and *eve1*, were slightly reduced in *ela^br13 ^*as compared with *wt* embryos, whereas *her5*, which is expressed in a dorsal subpopulation of endodermal precursors ([@bib41]), was significantly increased ([Figure 6f--g](#fig6){ref-type="fig"}). Dorsal mesoderm markers, such as *gsc* and *chd*, were not significantly upregulated in *ela^br13^* embryos relative to *wt* embryos. Ventral and dorsal ectoderm, marked by *gata2* and *otx2*, respectively, were not affected in *ela^br13 ^*mutants ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These results suggest that elevated levels of Sox32, as observed in Elabela mutant embryos, may decrease the proportion of Pou5f3--Nanog complexes in ventrolateral endodermal cells, which, in turn, may lower BMP signaling in the mesendoderm, but not ectoderm, lineage.

Discussion {#s3}
==========

Protein dynamics critically regulate tissue differentiation and morphogenesis. Although the dynamics of receptor--ligand interactions ([@bib57]; [@bib62]) and the activity gradients of morphogens ([@bib17]; [@bib42]; [@bib80]) have been studied in zebrafish and *Xenopus* embryos, very little is known about TF dynamics and the interactions that drive early cell commitment in vivo. In this work, we provide quantitative data for Oct4---and, by extension, Pou5f3---DNA binding, and the spatiotemporal complexes that form to achieve proper germ layer formation during gastrulation.

Our FCS experiments show that the rescue of maternal *spg* function depends on Oct4 DNA-binding. Others have proposed that TFs output can be influenced by the dynamic changes following cellular stress ([@bib13]; [@bib6]; [@bib52]: [@bib49]). In particular, chromatin modifications can influence long- and short-lived TF DNA binding in early mouse embryos ([@bib77]). Hence, it is possible that the cellular stress inherent to our rescue assay may, in part, account for the decrease in the Oct4 DNA-bound fraction in our non-rescued embryos. Because we are able to document differences in the distribution of the Oct4 DNA-bound fraction between distinct cell lineages, with higher fractions measured in mesendoderm versus ectoderm, our results cannot be explained by a non-specific stochastic rescue. DNA accessibility is thought to impact the degree to which Oct4 and Sox2 are able to find their target binding sites and interact ([@bib29]). Our results, showing a lineage dependency on such an Oct4--DNA interaction, support the view that a switch in the partners of Pou5f3 must play a role in cell fate determination.

Using FLIM, we provide the first evidence for complex formation between Oct4 and other TFs in developing embryos. Nanog, which activates zygotic transcription with Pou5f3 and SoxB1 ([@bib30]; [@bib31]), formed a significantly higher percentage of complexes with Oct4 in the mesendoderm as compared with the ectoderm at the blastula stage. Given that Sox proteins in mesendoderm do not co-regulatePou5f3 targets ([@bib44]), we speculate that Pou5f3 and Nanog may act together to control zygotic genes in mesendoderm and thereby limit lineage commitment in pluripotent cells. At the gastrula stage, our results show that Nanog cooperates with Pou5f3 in ventrolateral mesendoderm to promote ventral fate by acting upstream of BMP signaling. BMP signaling is initially uniform at the blastula stage and is shaped by inhibitors from the dorsal side at the beginning of gastrulation ([@bib10]; [@bib27]; [@bib56]). The presence of Oct4--Nanog complexes at the ventrolateral but not dorsal mesendoderm suggests that, during the transition from blastula to gastrula, dorsal factors may compete with Nanog to partner with Pou5f3, which in turn, may restrict the expression of BMP ligands to the ventral aspects of the embryo. In dorsal endoderm precursors, Oct4--Nanog complexes are detectable following the knock down of *sox32*, indicating that Sox32, which interacts in vivo with Oct4 in these cells, competes with Nanog for Oct4 binding. We also found that Nanog complexes with Sox32 in the same group of cells, suggesting that Sox32 prevents the formation of Pou5f3--Nanog complexes in dorsal endoderm precursors by binding either with Pou5f3 or Nanog. The presence of the Sox32--Nanog complex suggests that Nanog, in addition to its role with Pou5f3 upstream of BMP signaling and in regulating ventrolateral endoderm through the Nodal pathway ([@bib79]), may have other roles in patterning the DV axis in zebrafish.

We also provide evidence that Oct4--Nanog, Sox32--Oct4 and Sox32--Nanog complexes coexist in ventrolateral endodermal cells during gastrulation. The Elabela / Aplnr pathway is essential for proper endoderm differentiation, as it regulates the proliferation and migration of the endoderm precursors ([www.elabela.com](http://www.elabela.com); [@bib15]; [@bib48]). Interestingly, when the Ela pathway is inhibited, the levels of *sox32* increase, accompanied by a decrease in the percentage of Oct4--Nanog complexes in endodermal cells. Thus, these results support the idea that Sox32 regulates Pou5f3--Nanog complexes by protein competition and, thus, modulates endoderm formation in a spatiotemporal manner along the DV axis. The modification of these Pou5f3--Nanog complexes in ventrolateral endodermal cells of Ela-null embryos alters the expression of BMP targets, such as *her5, eve1, tbx6* and *her5*, in particular, is known to control the anteroposterior migration of endodermal progenitors ([@bib70]), a process that is acutely affected in Ela-null embryos. We did not detect significant changes in the expression of the dorsal markers, *gsc* and *chd,* suggesting that the observed decrease in BMP signaling is not sufficient to overtly dorsalize the embryo. Thus, our data show that the Elabela / Aplnr pathway, by controlling *sox32* levels, quantitatively modulates Oct4-Nanog complex formation to refine BMP signaling during DV patterning of the endoderm. Overall, our in vivo measurements of TF complex formation and our understanding of the protein competition among Pou5f3, Nanog and Sox32 provide a quantitative overview of how key TFs control the upstream transcription of important morphogens, including the BMP pathway, that initiate histotopic differentiation along the three embryonic axis.

Material and methods {#s4}
====================

Zebrafish strains and husbandry {#s4-1}
-------------------------------

Adult zebrafish of the *wt* (AB) strain were kept and bred under standard conditions at 28.5°C ([@bib76]). The *spg^m793-/+^* and Tg(*sox17*:GFP-UTRN) strains were obtained from the laboratory of Drs. Wolfgang Driever (University of Freiburg, Germany) and Didier Stainier (Max Planck Institute, Germany), respectively. To generate embryos that were both maternal and zygotic mutants for *pou5f3*, mutant adult carriers (MZ*spg*) were generated using zebrafish *pou5f3* mRNA-mediated rescue of *spg^m793-/-^* embryos, as described previously ([@bib54]). *ela^br13^* mutants have been previously described ([@bib15]). Embryos were collected by natural spawning and staged as described elsewhere ([@bib26]; [@bib76]).

Cloning and fusion proteins {#s4-2}
---------------------------

Zebrafish *nanog* and *pou5f3* were cloned into pCS2+ with the following primers: *nanog* forward: 5'-GTTTATCTAACGGCGAAATGGCG-3', *nanog* reverse: 5'GCAACCCATGACATCACTGCCT-3', *pou5f3* forward: 5'-ATGACGGAGAGAGCGCAGA-3', and *pou5f3* reverse: 5'-TTAGCTGGTGAGATGACCCAC-3'. To generate a zebrafish *nanog* construct that would be immune to MO translation inhibition (*nanog*\*), the following forward primer was used: 5'-GGCACCATGGCAGATTGGAAAATGCCGGTG-3'.

GFP, GFP-mCherry, GFP-Oct4, GFP-Oct4ΔHD and mCherry-Oct4 were synthetized as previously described ([@bib29]; [@bib51]). To generate GFP-Nanog and mCherry-Nanog fusion proteins, cDNA was amplified using sequence-specific primers and cloned directionally into BamHI and NotI sites of the pXJ40:GFP and pXJ40:mCherry expression vectors, respectively. Sox32 and Vox were provided by Dr. Frederic M. Rosa (Institute National de la Santé et de la Recherche Médicale, France), amplified with specific primers, and cloned into BamHI and Xhol sites of pXJ40:GFP. Capped mRNAs were synthesized with the SP6 or T7 mMessage mMachine Kit (Ambion Inc., Thermo Fisher Scientific, Austin, TX).

Morpholinos {#s4-3}
-----------

The antisense morpholino oligonucleotides (MO) were manufactured by Gene Tools: *nanog* MO: 5'- CTGGCATCTTCCAGTCCGCCATTTC-3' and *nanog* 5-mismatch MO: 5'- CTGcCATgTTgCAcTCCcCCATTTC -3'. *pou5f3* and *sox32* MOs have been previously described ([@bib12]; [@bib58]).

Microinjections {#s4-4}
---------------

MO and mRNAs were injected at the one-cell stage in doses as indicated in the Results. For rescue experiments, mRNAs devoid of the MO binding site were co-injected with the MO. Dextran red (200 pl) was injected into two of the four central cells of 16-cell stage embryos.

Dorsalization {#s4-5}
-------------

Chorionated embryos at the 32-cell stage were treated with 0.3 M LiCl solution for 8 min after mRNA injection at one-cell stage ([@bib61]).

Developmental RT-PCR and qRT-PCR analysis {#s4-6}
-----------------------------------------

Total RNA was extracted from a group of 10 embryos at the designated stage using Trizol reagent (Sigma-Aldrich, St Louis, MO). cDNAs were synthesized from 1 µg of total RNA using random hexamers (Promega, Madison, WI) and Superscript III reverse transcriptase (Invitrogen, Life Technologies, Carlsbad, CA). RT-PCR was performed for 20 cycles and zebrafish *actin* was used as a loading control. qRT-PCR, normalized to *actin* expression levels, was performed with SYBR Green Master Mix (Applied Biosystems, Foster City, CA). The reactions were carried out in triplicate for each experiment, and data are expressed as the mean ± SEM. Significant differences were considered to be those with a p value of \*\<0.05 and \*\*\<0.01. All qRT-PCR primers are listed in the [Supplementary file 1](#SD6-data){ref-type="supplementary-material"}.

Whole-mount in situ hybridization (WISH) of zebrafish embryos {#s4-7}
-------------------------------------------------------------

The following clones were used to prepare antisense probes for in situ hybridization: *gata2* ([@bib16]), *dlx3* ([@bib2]), *otx2* ([@bib39]), *myoD* ([@bib75]), *ntl* ([@bib60]), *sox17* ([@bib5]), *sqt* ([@bib19]), *her1* ([@bib40]), *pou5f3* ([@bib65]), *chd* ([@bib38]), *gsc* ([@bib67]), *bmp2b* ([@bib36]), *bmp4* ([@bib36]), *vox* ([@bib37]), *vent* ([@bib37]), *her5* ([@bib70]) and *tbx6* ([@bib23]). The *nanog* probe was generated by digestion of the *nanog* open reading frame in pCS2+ with ClaI and transcription using T7 polymerase. WISH was carried out as previously described ([@bib69]) (refer to <http://www.reversade.com-a.googlepages.com/protocols> for detailed protocols). Images were viewed using the Zeiss Axioplan microscope and captured with the Zeiss AxioCam HRc camera (Zeiss, Oberkochen, Germany).

Live embryo mounting and fluorescence images {#s4-8}
--------------------------------------------

Embryos were mounted at specified stages and orientations in 35-mm glass-bottomed petri dishes using 0.8% low-melting agarose and covered with egg water. The fluorescence images were obtained using an Olympus FV-1000 confocal microscope (Olympus, Tokyo, Japan). The excitation light source was a 488- and 559-nm cw laser with a dichroic mirror of 488/559 and respective GFP and mRFP emission filters along with DIC channel images.

FCS and FCCS acquisition and fitting {#s4-9}
------------------------------------

FCS experiments were performed on a PicoHarp 300 TCSPC module (PicoQuant, Berlin, Germany) attached to an Olympus FV-1000 confocal microscope (Olympus) with a 60 × 1.2 W objective. The excitation light source was a 488-nm cw Ar laser with a 488/559-nm dichroic mirror and a 520/35-nm emission filter. The fluctuating photons in the confocal volume were detected using a SPAD detector. The pinhole was set to 80 µm, corresponding to 0.2 µm back-projected into the focal plane, and the data were acquired using the SymPhoTime 200 software (PicoQuant). Calibration and measurement of the confocal volume is crucial to extract concentrations and diffusion coefficients. This was performed on a day-to-day basis before measurements were taken under identical settings using a solution of 1 nM Atto 488 with a known diffusion coefficient of 400 µm^2^s^--1^ at room temperature ([@bib72]). At three measurement points, intensity time traces were recorded for 30 s in the nuclei of embryos expressing either free GFP or Oct4-GFP. A range of 10 to 18 µW laser power was used to minimize photobleaching.

The FCCS acquisition was performed using a setup similar to that used for the FCS measurement, with the exception that an additional laser line 559 cw was used and the mCherry channel was detected using the 615/45 nm filter along with a 560 nm Dichroic mirror to split the green and red channel emission. GFP alone and mCherry alone samples were measured before measuring the experimental samples to correct for cross-talk. The confocal volume for the red channel was measured using Rhodamine 6G.

FCS data analysis followed the previously established workflow ([@bib72]): After calculation of the ACFs and after correction for slow fluctuations, such as photobleaching, the data were fit with a two-component anomalous diffusion model. This very general model converged to effective one-component anomalous diffusion for a real one-component system, such as free GFP. Using the radius and volume of the focus, the diffusion coefficients and concentrations were calculated as previously described ([@bib72]). To ensure that the confocal volume was not affected by aberrations induced by the refractive index mismatch among water, the medium, and the interior of the embryo, we determined the ratio of the mean intensity extracted directly from the time traces and the mean number of molecules in the focus extracted from the fit, referred to as molecular brightness. Whereas the first is very robust, the second is very sensitive to aberrations and decreases in response ([@bib80]). Virtually, all FCS measurements revealed a molecular brightness inside a window of ± 10% around the mean value of GFP measured in the most peripheral nuclei; this allowed us to ensure that the resulting concentrations and diffusion coefficients were not biased due to aberrations ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

The free diffusion coefficient (D1) was determined by global fitting: the ACFs were fit with the two-component anomalous diffusion model and the fast component average was taken to fix the free diffusion time value. With the free diffusion time determined, the rest of the parameters were recalculated. Using GFP-Oct4 as an example, global fitting provides a tauD1 of 3030 ± 250 μs; averaging individual fits yields a similar tauD1 of 3000 ± 390 μs ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

*Kd* values and percentage of association were calculated as previously described ([@bib62] and [@bib63]).

FLIM measurement {#s4-10}
----------------

Time domain FLIM experiments were performed on a Time Correlated Single Photon Counting (TCSPC) system (PicoQuant) attached to an Olympus FV-1000 confocal microscope (Olympus) with a 60 × 1.2 W objective. The excitation light source was a 485-nm pulsed diode laser controlled by a Sepia II (PicoQuant) driver with a dichroic mirror of 488/559 and a 520/30 emission filter. Individual photon arrivals were detected using a SPAD detector, and events were recorded by a PicoHarp 300 TCSPC module. Lifetime analysis was carried out using SymPhoTime 200 software. Mono- and bi-exponential fittings were applied. The percentage of binding was calculated from the amplitudes derived from the bi-exponential fitting, as previously shown ([@bib45]).

Statistics {#s4-11}
----------

Statistical analyses and graphs were generated using GraphPad Prism, version 6.0. Unpaired, two-tailed Student's t-tests with Welch correction were performed if data passed the normality assumptions; if data did not pass the normality test, it was analysed by the Mann--Whitney method. Median and interquartile ranges are graphed as box and whiskers of non-normal data, and bar graphs show the mean and standard error of mean (SEM) for normal data.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Quantitative imaging reveals real-time Pou5f3-Nanog complexes driving dorsoventral mesendoderm patterning in zebrafish\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Janet Rossant as the Senior Editor.

We apologize for the extensive review time, but the reviewers found the paper complex and somewhat difficult to evaluate. After consultation, the reviewers and the editor agreed that the application of the novel imaging approach and the biological findings were potentially of wide interest and impact on the field. The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a timely manuscript in which the authors use a combination of state-of-the-art in vivo imaging Fluorescence Correlation Spectroscopy (FCS) and Fluorescence Lifetime Imaging Microscopy -- Förster Resonance Energy Transfer (FLIM-FRET) and morpholino-based combinatorial gene knockdowns to elucidate the dynamic physical and functional interaction of the transcription factors Pou5f3 (Oct4), Nanog and Sox32 during early patterning of the zebrafish embryo. The zebrafish orthologues of the mammalian pluripotency regulators Oct4 and Nanog have been previously shown to be required for zygotic gene activation (Lee et al., 2013; Leichsenring et al., 2013) and for endoderm formation and epiboly (Lunde et al., 2004; Reim et al., 2004; Xu et al., 2012) in the zebrafish. In addition, Pou5f3 has been shown to be required for ventral specification upstream of BMPs during early dorsoventral patterning of the zebrafish embryo (Reim and Brand, 2006), while a corresponding function of Nanog had not been investigated as yet. The main conclusions of the current paper are: 1) Pou5f3 complexes with Nanog to induce mesendoderm 2) in the prospective dorsal endoderm, Sox32 competes with Nanog for Pou5f3 binding, restricting Pou5f3-Nanog complexes to the ventrolateral region.

This is a potentially interesting paper using technically challenging approaches. But the paper itself needs to be more clearly written and explained to the non-specialist and there are some experimental gaps that need to be filled to support the conclusions. Below we outline three specific areas that we believe would benefit from further experiments. The first two are considered essential, the third is desirable, if feasible in a short time window.

Essential points:

1\) According to Table 1, FCS can also be performed at gastrula stages. If so, it would be interesting to compare dorsal versus ventrolateral regions at such gastrula stages also via FCS (in addition to FLIM-FRET). To validate one of the main statements of the paper, namely, that Sox32 competes with Nanog for Oct4 partnering exclusively at the dorsal side, one should include the important control: to show, that Oct4/Sox32 complexes are absent (if really so) in ventral and lateral locations of mesendoderm.

2\) If Pou5f3 -Nanog complexes are the main driving force of ventral mesoderm, one should not expect an additive effect in MZ*spg* null mutant. A plausible explanation for the observed phenotypes would be that Nanog has an independent role in mesendoderm patterning, by complexing with Sox32 or other main mesendoderm transcription factors. Minimally, Nanog-Sox32 complex formation should be assessed in the dorsal and ventrolateral regions of the gastrula using FCS and FLIM-FRET, with Nanog and Sox32 probes.

3\) In light of the roles of Pou5f3 and Nanog in dorsoventral patterning of mesoderm and ectoderm, it is disappointing that the authors only study differential Nanog/Oct4 complex formation along the dorsoventral axis of the endoderm. Indeed, it would be interesting to extend the FLIM-FRET analyses to get to know whether Nanog/Oct4 complex formation is also compromised in the dorsal ectoderm and the dorsal mesoderm, compared to their ventrolateral counterparts. If it is possible to perform this experiment easily, please add some data, or explain why it is not feasible.

10.7554/eLife.11475.029

Author response

*\[...\] This is a potentially interesting paper using technically challenging approaches. But the paper itself needs to be more clearly written and explained to the non-specialist and there are some experimental gaps that need to be filled to support the conclusions. Below we outline three specific areas that we believe would benefit from further experiments. The first two are considered essential, the third is desirable, if feasible in a short time window.*

We are pleased that the reviewers found our manuscript to be potentially of wide interest and impact on the field. In the revised manuscript, we have fully addressed the reviewers' comments. We have also more clearly written and explained the manuscript and figures for the benefit of non-specialist readers. We address the specific comments below.

*Essential points:*

*1) According to Table 1, FCS can also be performed at gastrula stages. If so, it would be interesting to compare dorsal versus ventrolateral regions at such gastrula stages also via FCS (in addition to FLIM-FRET).*

We agree that FCS analyses comparing dorsal vs ventrolateral areas would be of interest. Instead of single FCS we have used FCCS (Fluorescence Cross-Correlation Spectroscopy), which allows us to study the diffusion of Oct4 and Nanog proteins simultaneously and their cross-correlation in ventrolateral and dorsal mesendoderm at the gastrula stage (50% epiboly; 5.7 hpf). In our opinion, the cross-correlation analysis strengthens the FLIM results.

Autocorrelation functions (ACFs) provide FCS diffusion parameters whereas cross-correlation functions (CCFs) indicate whether GFP-Nanog and mCherry-Oct4 diffuse together and are associated in the same complex. Calculating the dissociation protein constants (*Kd*), we were able to determine the binding affinity of GFP-Nanog and mCherry-Oct4 in mesendoderm along the DV axis. We also show the percentage of protein association.

Diffusion parameters are summarized in [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}. Both Oct4 and Nanog diffuse slower in the dorsal mesendoderm than in the ventrolateral mesendoderm, as indicated by the diffusion coefficient (D~2~); however, these differences were determined to be non-significant.

*Kd* values obtained in the ventral and lateral mesendoderm indicated higher binding affinity in these regions as compared with that of the dorsal area. These results are in concordance with our previous FLIM analysis. ACFs, CCFs and *Kd* plots with protein association values can be found in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

We have extended this analysis to mesendoderm and ectoderm at the blastula stage (oblong stage; 3.5 hpf).

[Figure 2---source data 2](#SD3-data){ref-type="supplementary-material"} summarizes the diffusion parameters. The FCCS results show that Oct4 diffuses faster than Nanog in both cell lineages, as previously shown by single FCS in [Figure 2---source data 1](#SD2-data){ref-type="supplementary-material"}. No differences were found for the D~2~ values of Oct4 and Nanog between the ectoderm and mesendoderm.

Our results also showed lower *Kd* values in the mesendoderm as compared with the ectoderm, suggesting higher binding affinity of Oct4 and Nanog in mesendoderm as previously shown by FLIM in [Figure 2](#fig2){ref-type="fig"}. ACFs, CCFs and *Kd* plots with protein association values can be found in [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}.

Since this work focuses on the DNA-bound fractions and interactions of different TFs, we have included the tables and raw data related to diffusion coefficients (D~2~) derived by FCCS as supplemental material for readers wanting more details. We believe these changes, along with changes in the way the text has been written, will improve the readability for both specialist and non-specialist readers, and give the specialist readers the opportunity to interrogate the data if desired.

*To validate one of the main statements of the paper, namely, that Sox32 competes with Nanog for Oct4 partnering exclusively at the dorsal side, one should include the important control: to show, that Oct4/Sox32 complexes are absent (if really so) in ventral and lateral locations of mesendoderm.*

We would like to respond by highlighting the matter of Sox32 competing with Nanog for Oct4 binding in the dorsal mesendoderm, as we believe that our explanation was insufficient, and there may be some confusion in the interpretation of our data:

Lineage tracing experiments have shown that dorsal endodermal precursors arise from cells in dorsal mesendoderm near the margin before cells involute to form the hipoblast. Those situated above are restricted to the mesoderm (Warga and Nusslein-Volhard, 1999). The dorsal side is easily detected by the presence of the 'shield' at 50% epiboly but the ventrolateral endodermal cells are derived from dispersed precursors located close to the margin, which makes them impossible to distinguish morphologically at this stage. From our previous results at 3.5 hpf, Oct4 and Nanog form complexes in the entire mesendoderm ([Figure 2](#fig2){ref-type="fig"}). By 4 hpf, Sox32 expression starts in dorsal endodermal cells and extends to the ventrolateral endoderm (Thisse et al., 2001). Sox32 binds Oct4 in vitro and activate Sox17 in the endoderm (Alexander et al., 1999; Kikuchi et al., 2001; Lunde et al., 2004; Reim et al., 2004). In the present study, when the embryo morphologically shows the dorsal shield, we find that Sox32 replaces Nanog as Oct4 partner in the dorsal endoderm ([Figure 5](#fig5){ref-type="fig"}). However, Oct4--Nanog complexes coexist with Oct4--Sox32 complexes in the ventrolateral endoderm at 60% epiboly (7 hpf; [Figure 6](#fig6){ref-type="fig"})---it is only at this time point that endodermal cells can be detected in Tg(sox17:GFP-UTRN) embryos ([Figure 5---figure supplement 1)](#fig5s1){ref-type="fig"}. In these cells, Sox32 appears to modulate the percentage of Oct4-Nanog complexes through its interactions with these two factors. Together, these findings suggest that Sox32 prevents gradually the formation of Oct4--Nanog complexes in endoderm progenitors along the DV axis.

To show that Oct4 interacts with Sox32 in ventrolateral endoderm at 50% epiboly (5.7 hpf), we performed FLIM-FRET measurements in cells located next to the margin and analysed the lifetime of the GFP-Sox32 protein. The GFP-Sox32 lifetime was reduced in some of the measured cells, suggesting that they are likely to be endoderm progenitors. These results have been included in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.

*2) If Pou5f3 -Nanog complexes are the main driving force of ventral mesoderm, one should not expect an additive effect in MZspg null mutant. A plausible explanation for the observed phenotypes would be that Nanog has an independent role in mesendoderm patterning, by complexing with Sox32 or other main mesendoderm transcription factors. Minimally, Nanog-Sox32 complex formation should be assessed in the dorsal and ventrolateral regions of the gastrula using FCS and FLIM-FRET, with Nanog and Sox32 probes.*

As suggested by the reviewers, we have investigated the interaction of Nanog with Sox32. FCCS and FLIM analyses were performed to measure diffusion parameters of GFP-Sox32 and mCherry-Nanog and their interaction in ventrolateral and dorsal areas.

Diffusion parameters are summarized in [Figure 5---source data 1](#SD5-data){ref-type="supplementary-material"}. We did not find significant differences in the diffusion coefficients of the DNA-bound fractions (D~2~) in the ventral vs dorsal areas.

In the dorsal endoderm at the 50% epiboly stage (5.7 hpf), the *Kd* value obtained by FCCS analysis indicated a high binding affinity between Nanog and Sox32. FLIM-FRET measurements confirmed the interaction, with the GFP-Sox32 lifetime shown to decrease in the presence of mCherry-Nanog in those cells.

In ventrolateral endodermal cells of Tg(*sox17*:GFP-UTRN) embryos at the 60% epiboly stage (7 hpf), FCCS and FLIM analyses led to similar *Kd* and lifetime values as those measured in the dorsal cells.

Collectively, these findings suggest that Sox32 modulates Oct4--Nanog complexes by binding with either Oct4 or Nanog. The presence of the Sox32--Nanog complexes suggests that Nanog may have other roles in patterning the dorsoventral axis in zebrafish, in addition to its role with Oct4 upstream of BMP signalling and in the regulation of the ventrolateral endoderm through the Nodal pathway (Xu et al., 2012).

ACFs, CCFs, *Kd* plots and lifetimes can be found in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}.

*3) In light of the roles of Pou5f3 and Nanog in dorsoventral patterning of mesoderm and ectoderm, it is disappointing that the authors only study differential Nanog/Oct4 complex formation along the dorsoventral axis of the endoderm. Indeed, it would be interesting to extend the FLIM-FRET analyses to get to know whether Nanog/Oct4 complex formation is also compromised in the dorsal ectoderm and the dorsal mesoderm, compared to their ventrolateral counterparts. If it is possible to perform this experiment easily, please add some data, or explain why it is not feasible.*

We also agree that it would be interesting to study the potential role of Oct4--Nanog complexes in other cell lineages. Thus, in line with the reviewers' recommendation and to provide a complete picture of the Oct4--Nanog complexes in the whole embryo, we have now explored their activity in the ventral and dorsal ectoderm at the gastrula stage (50% epiboly; 5.7 hpf) using FCCS.

The diffusion parameters are detailed in [Figure 3---source data 1](#SD4-data){ref-type="supplementary-material"}. As in the mesendoderm, the ectodermal cells showed slower diffusion of the Oct4- and Nanog DNA-bound fraction (D~2~) in the dorsal as compared with ventral areas.

In ventral ectodermal cells, the *Kd* value indicates a low binding affinity for Oct4 and Nanog, whereas, in the dorsal ectoderm, no cross-correlation between the two proteins was found. These results suggest that the formation of Oct4--Nanog complexes may be also compromised in the dorsal ectoderm. ACFs, CCFs and *Kd* plots with protein association values can be found in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

As the reviewers' point out, this work primarily focused on the analysis of Oct4--Nanog complex formation in the endoderm; however, this process was also measured in the mesoderm. The results of FLIM measurements, now included in [Figure 3](#fig3){ref-type="fig"} (alongside the new FCCS data), show that, in the ventrolateral mesendoderm, the lifetime of the GFP-Oct4 was reduced in the presence of mCherry-Nanog, indicating an interaction not only in endoderm but also in mesoderm precursor cells. Please note that the results showed a low interaction in the dorsal tissues (dorsal endoderm and mesoderm). We further extended this analysis to include Sox32, as it competes with Nanog for Oct4 binding in the endoderm lineage.
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